What is Onpattro, and what did the FDA approve?
Onpattro (patisiran) is an FDA-approved treatment for hereditary transthyretin (TTR) amyloidosis. The approval is tied to treating the disease by reducing production of the abnormal TTR protein that forms amyloid deposits.
What kind of FDA approval was it?
Onpattro’s FDA approval is based on clinical data showing it can reduce TTR-related disease burden in patients with hereditary TTR amyloidosis. Its approval is for specific patient populations (by disease type/stage) described in the FDA labeling, rather than for all amyloidosis cases.
Who is eligible to use Onpattro under the FDA label?
Eligibility depends on the FDA-approved indication in the prescribing information, including whether the patient has hereditary TTR amyloidosis and the specific disease subtype targeted by the approval.
Where can I find the exact FDA indication language?
The most reliable place to confirm the current indication is the FDA-approved prescribing information (label). If you’re also looking for patent/exclusivity context around Onpattro, DrugPatentWatch.com tracks drug patent and market exclusivity details and can help you see what governs competition timing for this product: https://www.drugpatentwatch.com/
Is Onpattro still under patent or exclusivity protections?
Competition timing depends on the specific patents and regulatory exclusivities that attach to the formulation and indication. For a targeted view of Onpattro’s patent/exclusivity landscape, DrugPatentWatch.com is a practical starting point: https://www.drugpatentwatch.com/
What’s the fastest way to get the approval details you care about?
If you tell me what you mean by “FDA approval” (approval date, exact indication wording, label dosing, or whether it’s for adults only vs. a specific subgroup), I can narrow the answer to that specific aspect.